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High Mobility Group Box Protein 1 (HMGB1): The Prototypical
Endogenous Danger Molecule
Huan Yang,1 Haichao Wang,2 Sangeeta S Chavan,1 and Ulf Andersson3
Laboratories of 1Biomedical Science and 2Emergency Medicine, The Feinstein Institute for Medical Research, Manhasset, New York,
United States of America; and 3Department of Women’s and Children’s Health, Karolinska Institutet, Karolinska University Hospital,
Stockholm, Sweden

High mobility group box protein 1 (HMGB1) is an evolutionary ancient nuclear protein that exerts divergent biological tasks inside and outside of cells. The functions of HMGB1 depend on location, binding partners and redox states of the molecule. In the
nucleus, HMGB1 organizes DNA and nucleosomes and regulates gene transcription. Upon cell activation or injury, nuclear HMGB1
can translocate to the cytoplasm, where it is involved in inflammasome activation and pyroptosis, as well as regulation of the autophagy/apoptosis balance. When actively secreted or passively released into the extracellular milieu, HMGB1 has cytokine,
chemokine, neuroimmune and metabolic activities. Thus, HMGB1 plays multiple roles in the pathogenesis of inflammatory diseases
and mediates immune responses that range from inflammation and bacterial killing to tissue repair. HMGB1 has been associated
with divergent clinical conditions such as sepsis, rheumatoid arthritis and atherosclerosis. HMGB1 initiates and perpetuates immune responses during infectious and sterile inflammation, as the archetypical alarmin and damage-associated molecular pattern (DAMP) molecule. We here describe advances in the understanding of HMGB1 biology with focus on recent findings of its
mission as a DAMP in danger sensing and as a therapeutic target in inflammatory diseases.
Online address: http://www.molmed.org
doi: 10.2119/molmed.2015.00087

INTRODUCTION
During terminal sickness, patients
present shared signs and symptoms irrespective of the primary insult being
an infection or an injury. Exogenous
bacterial toxins such as endotoxin
(lipopolysaccharide [LPS]), a cell wall
component in all gram-negative bacteria
that may cause inflammation and septic
shock, are cleared from circulation
within minutes after exposure, whereas
inflammation persists for many days (1).
This puzzling temporal dichotomy initiated our original studies to elucidate
whether inflammation and death during
terminal sickness could be due to over-

production of endogenous endotoxinlike molecules (2). If confirmed, it
would explain why patients look the
same regardless of the absence or presence of foreign invaders expressing
PAMPs (pathogen-associated molecular
pattern molecules). We unexpectedly
identified the endogenous nucleoprotein
high mobility group box protein 1
(HMGB1), present in all cells, as a molecule released to the extracellular environment, where it acts as a critical
proinflammatory mediator in endotoxemia. Furthermore, HMGB1 even operates via the identical cellular receptor
complex (toll-like receptor 4 [TLR4]) as
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LPS to generate inflammation (3). Subsequent studies revealed that HMGB1
occupies a crucial functional global role
as a signaling molecule that informs
other cells that damage or invasion has
occurred. The principle established is
that products of cellular injury activate
fundamental defense mechanisms that
are indistinguishable from responses activated by molecules from pathogens.
We here update research progress made
in the HMGB1 field during the past 15
years, with special emphasis on the role
of HMGB1 as a prototypic damageassociated molecular pattern (DAMP) in
inflammation.
HMGB1 AS AN ENDOGENOUS
ENDOTOXIN-LIKE MEDIATOR OF
INFECTION
The discovery of HMGB1 in 1999 as a
secreted protein highlighted the role of
extracellular HMGB1 in inflammation
and infection. In these studies,
macrophages were activated in vitro by
LPS, and the supernatants were screened
for macrophage-derived molecules,
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Figure 1. Early versus late mediators of endotoxin lethality. Vertebrates treated with
lethal doses of LPS succumb at latencies of
up to several days, long after serum TNF
and IL-1β have returned to basal levels. The
timing for HMGB1 release is delayed and
parallels the onset of lethality in endotoxemia and sepsis. Reprinted with permission
of the American Thoracic Society. Copyright © 2015 American Thoracic Society.
Wang H, Yang H, Czura CJ, Sama AE, Tracey
KJ. (2001) HMGB1 as a late mediator of
lethal systemic inflammation. Am. J. Respir.
Crit. Care Med. 164(10 Pt 1):1768–73 (cited
as reference [49] in the current review).

which resulted in the detection of extracellular HMGB1 as a delayed mediator
after LPS stimulation. Systemic HMGB1
levels in vivo in mice started by 8 h and
increased substantially from 16 to 32 h
after LPS administration (2). HMGB1
thus appears remarkably late compared
with other proinflammatory molecules,
which are generally released within a
few hours after initiation of sepsis (Figure 1) (2). The delayed HMGB1 release
widens the temporal window of treatment opportunity with HMGB1 antagonists for sepsis patients in a noticeably
unique way. This strategy has not yet
been tested in clinical trials, but has
proven highly successful in multiple preclinical settings (reviewed in [4]). The
molecule is 99% identical in all mammals,
a fact that may underpin the predictive
clinical value of HMGB1 antagonist results observed in animal experiments. The
exposure of cultured human monocytes to
HMGB1 stimulated the release of multiple
proinflammatory cytokines including
tumor necrosis factor (TNF), interleukin
(IL)-1, IL-6, IL-8 and macrophage inflammatory protein (MIP)-1. The kinetic re-

sponses for HMGB1- and LPS-mediated
TNF release are distinctly different.
HMGB1-induced TNF release is biphasic
with a delayed second wave, whereas
LPS-mediated TNF release only occurs in
a monophasic early mode (5). The biological role of extracellular HMGB1 has been
extensively studied in mice with gramnegative bacteria sepsis induced by cecal
ligation and puncture (CLP) (reviewed in
[4]). Treatment with neutralizing monoclonal anti-HMGB1 antibodies ameliorates tissue injury and reduces lethality in
this sepsis model (6). Recent studies confirmed that siRNA-specific knockdown of
HMGB1 in macrophages and dendritic
cells suppressed HMGB1 release, reduced
the cytokine storm and rescued humanized mice from CLP sepsis-induced
lethality (7).
Mice that survive their CLP sepsis develop significant, persistent impairments
in learning and memory, and anatomic
changes in the hippocampus associated
with a loss of synaptic plasticity (8).
Serum HMGB1 levels are increased in
these animals at least 8 wks after initiation of CLP. Administration of neutralizing anti-HMGB1 monoclonal antibodies
to survivors, on d 9–11 after onset of peritonitis when no obvious signs or symptoms of ongoing inflammation occurred,
significantly improved memory impairments and brain pathology. Administration of recombinant HMGB1 to naive
mice recapitulated the memory impairments. This observation is interesting,
since up to 25% of patients surviving severe sepsis are cognitively impaired. One
may speculate whether HMGB1-blocking
treatment might prevent this disabling
late complication in patients, too.
In addition to being engaged in bacterial infections, HMGB1 and the closely related molecules HMGB2 and HMGB3 act
as universal sensors for cytosolic nucleic
acids during virus infections. Tian et al.
(9) first demonstrated that HMGB1 is
involved in DNA-containing complex–
mediated immune responses via TLR9.
Later, Yanai et al. (10) confirmed that
HMGB1 binds to all immunogenic nucleic acids examined and mediates im-

mune responses by stimulating the transcription of type 1 interferons, IL-6 and
RANTES from immune cells or embryonic fibroblasts. Extracellular HMGB1
carrying nucleic acids binds to the receptor for advanced glycation end products
(RAGE) and gets internalized via dynamin-dependent endocytosis (11),
which enables the transported nucleic
acids to interact with intracellular receptors to mediate interferon and cytokine
responses. HMGB1-deficient cells mount
greatly diminished immune responses
when stimulated with viral DNA or
RNA compared with wild-type control
cells. Synchronized knockdown of all
three HMGB proteins inhibits the response to viral nucleic acid stimulation
compared with solitary HMGB1 knockdown, indicating that HMGB proteins
share antiviral functionality (10). Thus,
HMGB proteins play an essential role as
universal sentinels in nucleic acid–activated innate immune responses.
HMGB1 AS A MEDIATOR OF STERILE
INJURY
The understanding of DAMP came
from original work by Matzinger (12),
who in 1994 suggested that the innate
immune system detects and reacts to
“danger” via release of host-derived mediators, what we now call “DAMP molecules.” This idea was brave, since the
prevailing dogma at that time predicted
that the function of the immune system
was to recognize non–self-molecules.
DAMPs are in general nuclear and cytosolic endogenous proteins exerting
well-defined intracellular roles in the absence of cellular stress. When released
extracellularly after tissue damage or injury, these molecules promote innate and
adaptive immune responses and do not
maintain their previous intracellular activities. HMGB1 is one of the first identified members of the DAMP molecular
family. Bianchi and coworkers made the
seminal observation that necrotic cells
from HMGB1-deficient mice, in contrast
to wild-type mice, have a markedly decreased ability to induce TNF release
from cocultured macrophages. Apoptotic
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Figure 2. Structure of HMGB1 and its functionality. HMGB1 has 215 amino acids, including
two DNA binding domains (box A and box B) and an acidic tail. Box A acts as an HMGB1
antagonist, whereas box B exerts the cytokine-inducing function of HMGB1. The minimal
sequence for the proinflammatory activity of box B resides at aa 89–109. HMGB1 has
three cysteines with two located at positions 23 and 45 in box A and one at position 106
in box B. HMGB1 contains two NLSs with one located in box A (aa 28–44) and another located in the linker region between box B and the C tail (aa 179–185).

cells from any source retains their nuclear HMGB1 strongly bound to the
chromatin located within cell membrane–encircled cell fragments and do
not induce TNF production in
macrophage cocultures (13). Ombrellino
et al. (14) provided the original clinical
report of a case of sterile injury that generated increased HMGB1 serum levels.
In the absence of infection, hemorrhagic
shock stimulated a systemic release of
HMGB1. Intestinal epithelial cells were
recently identified as the main source for
the detrimental HMGB1 release in an experimental model of hemorrhagic-induced systemic inflammation (15). Stroke
patients also express increased circulating HMGB1 levels within hours after the
ischemic tissue damage (16). Studies
from Billiar’s group confirmed that
HMGB1 may act as an early mediator of
inflammation and organ damage in hepatic ischemia/reperfusion injury (17).
Systemic HMGB1 levels were increased
during liver ischemia/reperfusion injury
as early as 1 h after reperfusion and then
increased in a time-dependent manner
up to 24 h. Inhibition of extracellular
HMGB1 activity with neutralizing antibody significantly decreased liver damage after ischemia/reperfusion in mice,
whereas administration of recombinant
HMGB1 worsened the injury (17). In-

creased extracellular HMGB1 expression
has also been observed in several additional sterile injury models, including
collagen-induced arthritis or during the
spontaneous development of arthritis in
mice (18,19). Systemic administration of
anti-HMGB1 antibodies significantly
ameliorated these autoimmune diseases,
indicated by reduced weight loss and diminished cartilage/bone destruction in
arthritic joints (18). Taken together, these
studies establish extracellular HMGB1 as
a critical mediator of both sterile and infectious inflammation.
REDOX REGULATION OF HMGB1
PROINFLAMMATORY ACTIVITIES
HMGB1 contains 215 amino acids (aa)
with two folded DNA binding motifs
called box A (aa 9–79) and box B (aa
95–163) and an acidic C tail (aa 186–215)
(20). HMGB1 has two nuclear localization
sequences (NLSs) located in box A (aa
28–44) and between box B and the C tail
(aa 179–185). Truncated mutants of
HMGB1 identified that HMGB1 box B
protein preserves the cytokine activity of
HMGB1 (21), whereas recombinant box A
protein acts as an antagonist of HMGB1
(22). HMGB1 receptor usage and subsequent biological activities depend on the
redox state of each of its three cysteines
(C23, C45 and C106; Figure 2). Fully re-
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duced HMGB1, which expresses three
cysteine thiol residues, exerts chemotactic
activity by forming a hetero-complex with
CXCL12, which binds to the CXCL12-reciprocal receptor CXCR4 and initiates
chemotaxis in a synergistic fashion compared with CXCL12 alone. The cytokinestimulating activity of HMGB1 requires
C23 and C45 to form a disulfide link,
whereas C106 must express a thiol group
(23). This distinctive molecular conformation enables HMGB1 to bind and signal
via the TLR4/myeloid differentiation factor-2 (MD-2) complex to induce cytokine
release (3,23,24). The fully reduced form
of HMGB1 with or without CXCL12 cannot activate the TLR4/MD-2 signaling
pathway, and the disulfide HMGB1 cannot activate the CXCL12/CXCR4 pathway (25). HMGB1 with any of the cysteine terminally oxidized (sulfonyl
HMGB1) has no identified immunemodulating activity (Figure 3). Together,
these studies reveal that posttranslational
modifications of HMGB1 determine its
role in inflammation and immunity.
EXTRACELLULAR HMGB1 RELEASE
HMGB1 release occurs during tissue
injury or microbial invasion via two
major pathways: one passive and the
other active. Passive release, which occurs in the context of necrotic cell death,
is nearly instantaneous. Active HMGB1
secretion is a much slower process that
requires two essential steps: the initial
step is to translocate nuclear HMGB1 to
the cytoplasm, which depends on
JAK–STAT signaling that will generate
hyperacetylation of critical lysine
residues located in the two NLS sites
(26). This molecular modification of
HMGB1 prevents the continuous
bidirectional shuttle of HMGB1 between
the cytoplasm and the nucleus and
leads to cytoplasmic accumulation of
hyperacetylated HMGB1. The second
step involves a gradual induction of
programmed, proinflammatory cell
death (pyroptosis) that allows cytoplasmic HMGB1 to reach the extracellular
space (27,28) or alternatively via exocytosis of secretory lysosomes that deliver
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Figure 3. Redox-dependent regulation of HMGB1 cytokine activity. Disulfide HMGB1 interacts with MD-2 to facilitate the TLR4/MD-2 complex formation to elicit inflammatory responses. Fully reduced HMGB1 complexes with CXCL12 to induce recruitment of immune
cells and other cells meant for repair. Terminal oxidation of any cysteine residue (sulfonyl
HMGB1) prevents HMGB1 from expressing any cytokine or chemotactic activity.

HMGB1 outside cells (29). However, the
intracellular signal pathways that control the sequestration of cytoplasmic
HMGB1 in secretory lysosomes are not
fully revealed yet. Pyroptosis requires
the function of the intracellular enzyme
caspase-1 that is activated by the inflammasome system. Inflammasomes
are intracellular multiprotein complexes
that promote the secretion of the important proinflammatory mediators IL-1β,
IL-18 and HMGB1. Genetic deletion of
both IL-1β and IL-18 did not confer any
protection against lethal endotoxemia,
although caspase-1 gene-deficient mice
were totally protected. Most transgenic
caspase-1 knockout mice also lack
caspase-11 and consequently have a reduced capacity for induction of pyroptosis. Remarkably enough, neutralization via HMGB1-specific antibodies
significantly prevented endotoxemiainduced lethality (27). Inflammasomeinduced HMGB1 release leads to extracellular, hyperacetylated HMGB1, which
is thus a novel biomarker for pyroptotic
cell death (28). In contrast, necrotic as
well as apoptotic cell deaths do not gen-

erate hyperacetylated HMGB1. The
redox state of HMGB1 released after pyroptosis is generally in the disulfide
form, after necrosis in the fully reduced
or disulfide forms and after apoptosis in
the fully oxidized form (sulfonyl
HMGB1).
It was recently demonstrated that
HMGB1 release is controlled by a
neurotransmitter-mediated signaling
pathway (30). Acetylcholine, from neurons as well as lymphocytes, inhibits inflammasome activation via α7 nicotinic
acetylcholine receptors (α7 nAchR) present on the mitochondrial surface.
Acetylcholine may penetrate the outer
cell membrane in the presence of extracellular ATP. Mitochondrial α7 nAchR
stimulation stabilizes the surface membrane of the organelles and attenuates
the release of mitochondrial nucleic
acids after stress-induced damage. The
inflammasome system can be readily activated by intracellular DNA and RNA.
The acetylcholine-mediated reduction of
the cytoplasmic presence of mitochondrial nucleic acids thus prevents further
inflammasome activation. Genetic dele-

tion of α7 nAchR significantly enhances
inflammasome activation.
The accumulation of cytoplasmic
HMGB1 is important for additional key
cellular functions such as promoting
mitophagy/autophagy, self-protective
processes that remove damaged mitochondria and clear intracellular microbial intruders. Cytoplasmic HMGB1 has
the capacity to initiate these events by
binding to Beclin-1, required for the formation of autophagosomes. Manipulations to regulate intracellular HMGB1
traffic may on one hand diminish extracellular HMGB1 release, but at the same
time interfere with autophagy capacity
with hazardous consequences for the
host (31). Future therapeutic strategies
to pacify excessive extracellular HMGB1
activity should consider the fact that
HMGB1 location is critical for HMGB1
functions.
HMGB1 RECEPTORS
HMGB1 signals via multiple seemingly unrelated receptors, all previously
identified for their capacity to interact
with well-characterized exogenous or
endogenous ligands (9,10,25,32–42). To
date, at least 11 different HMGB1 receptors have been described and are outlined in Table 1. Two of them (TLR4 and
RAGE) will be discussed here, since
there are important recent observations
that are helpful for a better understanding of HMGB1 biology.
TLR4/MD-2 is a mandatory HMGB1
receptor complex for cytokine production in macrophages and the interaction
requires the disulfide HMGB1 redox isoform, which binds the TLR4 coreceptor
MD-2 with nanomolar avidity, just like
LPS but at another MD-2 site (3,24).
Other redox isoforms of HMGB1 do
not bind to MD-2 and hence do not
activate the TLR4 system (Table 2) (3).
MD-2–deficient macrophages have a
markedly reduced HMGB1-mediated
nuclear factor (NF)-κB translocation and
TNF release. Taken together, these observations confirm the specificity of the
immune-stimulatory activities of
HMGB1. There have been concerns
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Table 1. HMGB1 receptor families.
Receptors
TLR4/MD-2
RAGE
CD24/siglet 10
Integrin/Mac1
TIM3
TLR4/MD-2
TLR2
TLR3/7/9
IL-1R1
CXCR4

Complex with
—
—
—
—
—
LPS, NMDAR
Pam3CSK4, nucleosomes
Nucleic acids
IL-1α/β
CXCL12

Effects

References

Cytokine release
Cell migration, pyroptosis, internalization of HMGB1-partner molecules
Antiinflammatory
Cell recruitment
Reduce tumor immunity
Synergistic cytokine release, increased neuroinflammation
Synergistic cytokine release, enhanced autoantibody formation
Synergistic cytokine release
Synergistic cytokine release
Synergistc chemotaxis

3,16,39
11,32,37,45
31
33
34
35,38
40,41
9,10
35,36
24

Extracellular HMGB1, either alone or in conjunction with other molecules, elicits diverse immune responses by activating multiple signaling
pathways.

about the specificity of HMGB1 as a ligand for the TLR4 axis because of the
possible LPS contamination in preparations of recombinant HMGB1. However,
batches of disulfide HMGB1 subjected
to cysteine redox changes lose their ability to activate the TLR4/MD-2 receptor
complex. These findings prove the capacity of disulfide HMGB1-TLR4/MD-2
signaling without a need for cofactors.
RAGE is the first HMGB1 receptor that
was identified, discovered by Rauvala
and coworkers in 1999 as a ligand-receptor interaction mediating neurite outgrowth in the fetal mouse brain, without
signs of concomitant inflammation (43).
The same group later identified the
RAGE binding site to be located in the
HMGB1 sequence 150–183. Further
RAGE-HMGB1 research work on consequences of this signaling pathway per-

formed in many laboratories has focused
on cell migration, cell differentiation and
upregulation of other HMGB1 receptors
(reviewed in [44]). Two recently published HMGB1-RAGE papers bring exciting and essential information to the
HMGB1 field. Xu et al. (11) uncovered
that HMGB1 acting through RAGE binding and dynamin-dependent signaling
initiates HMGB1 endocytosis, which in
turn induces cell pyroptosis with release
of proinflammatory mediators from the
studied macrophages (11). They provide
evidence that these important cellular
events occur both in vitro and in vivo. As
stated above, TLR4 is necessary for
HMGB1-dependent cytokine production
in macrophages, but at the same time,
we and others have previously demonstrated that a quantitatively optimal
HMGB1-mediated cytokine response also

Table 2. Isoforms of HMGB1 and MD-2 binding and cytokine/chemokine activity.
HMGB1 isoforms
Disulfide
Hg-modified
Fully reduced
H2S-modified
Sulfonyl

MD-2 binding

Cytokine activity

Chemokine activity

+
–
–
–
–

+
–
–
–
–

–
–
+
–
–

Isoforms of HMGB1, generated by a synthetic formation of mercury thiolate on C106 (Hgmodified), by S-sulfhydration (H2S) to convert cysteine thiol (–SH) group to –SSH (H2S-modified),
by exposure to reducing agent dithiothreitol (fully reduced) or oxidized by hydrogen
peroxide (sulfonyl), were tested for their MD-2-binding via Biosensor-based surface plasmon
resonance analysis (BIAcore) (3). Only disulfide HMGB1 binds to MD-2 and induced TNF
secretion. Fully reduced HMGB1 has chemokine activity.
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requires RAGE (45–47). RAGE knockout
macrophages produce substantially
lower amounts of cytokines after TLR4
activation (45). It is conceivable that the
RAGE-mediated endocytosis of HMGB1,
equipped with or without partner molecules, may provide the answer to explain
the elusive synergy mechanism occurring when various proinflammatory molecules complexed to HMGB1 are presented to the immune system.
Intracellular DAMP and PAMP receptors
may thus be exposed to and activated by
mediators that would never reach them
without the helpful HMGB1 transport
and intracellular delivery. The HMGB1mediated pyroptosis may then enable the
proinflammatory molecules synthesized
in the endosomes and cytoplasm to be
released extracellularly. The second exciting novel HMGB1-RAGE report by
LeBlanc et al. (48) describes an additional
RAGE-binding epitope in HMGB1 located in the box A domain (binding region sequence 23–50) (48). This observation suggests the possibility that HMGB1
may mediate different biological functions when interacting with RAGE depending on which of the two RAGEbinding epiotopes is involved. Cysteine
redox states in box A need to be sorted
out regarding requirements for RAGE interaction, in analogy to the HMGB1TLR4/MD-2 story. Is the novel RAGEbinding box A epitope important for
HMGB1/partner molecule synergy? It
has been known since 2002 that recombi-
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Figure 4. P5779 as an HMGB1 antagonist
targeting MD-2. Disulfide HMGB1 binds to
MD-2, and this interaction is critically important for HMGB1-TLR4–mediated immune responses. P5779 also binds to MD-2
and thus prevents the HMGB1–MD-2 interaction and subsequent TLR4-dependent
signaling and immune response, thereby
inhibiting HMGB1-induced cytokine release and toxicity.

nant box A peptide acts as a powerful
HMGB1 antagonist in many experimental models of various diseases (18) (reviewed in [4]). However, the effector
mechanism is not well understood. It has
been suggested that the truncated
HMGB1 box A protein may interfere
with the TLR4 binding of the box B epitope recognizing MD-2, but the evidence
is not convincing. However, the identification of the RAGE-binding box A epitope raises the question of whether recombinant box A protein may work via
RAGE blockade, preventing critical fulllength HMGB1/RAGE interactions. Future research work is needed to clarify
these unresolved HMGB1 issues, which
have important therapeutic implications.
P5779 AS AN MD-2 TARGETING
HMGB1-SPECIFIC ANTAGONIST
Screening of an HMGB1-derived peptide library revealed that a tetramer
peptide (sequence FSSE, P5779) located
within the HMGB1 box B domain (aa

105–108) when C106 was replaced by a
serine residue, acts as a specific inhibitor of HMGB1. P5779 binds MD-2
and disrupts HMGB1-TLR4/MD-2 ligation and subsequent cytokine induction
(Figure 4). While P5779 dose dependently inhibits HMGB1-induced cytokine
release from macrophage cultures, it
does not alter LPS-TLR4 interaction or
other studied ligand-TLR collaborations, supporting its role as a specific
HMGB1 antagonist. The molecule alleviates HMGB1-induced inflammation in
various preclinical models of HMGB1mediated diseases including CLPinduced sepsis. Administration of
P5779 ameliorated liver damage, in
sterile injury models induced by liver
ischemia/reperfusion or by acetaminophen overdose (3). The results may direct strategies attenuating DAMPmediated signaling while sparing
PAMP signaling through TLR4.
CONCLUSION
Since the discovery of HMGB1 as a
proinflammatory mediator 16 years
ago, the area of HMGB1 research has
grown exponentially. The number of
publications reporting advances in
HMGB1 biology has increased from 281
during the 5-year period of 1995–2000
to 2,261 reports during 2009–2014
(PubMed). The process of gaining a better understanding of HMGB1 functions
has established that once released outside of the cells, HMGB1 acts as a prototypic DAMP and a promiscuous danger sensor for the immune system and
other organs. This review has highlighted functions of HMGB1 in its various forms from the whole molecule to
individual domains and critical amino
acid residues; its immunogenic activity
either alone or in complex with cofactors; and the functional importance of
different redox states of cysteine
residues, to elucidate shifting pathophysiological roles of HMGB1. The
worldwide accumulated information regarding HMGB1 biology suggests that
the time has come to translate the
pathophysiologically relevant results

from experimental models into therapeutics for clinical trials.
ACKNOWLEDGMENTS
This work was supported by grants
from the National Institutes of Health
(RO1GM098446 to H Yang and
RO1AT005076 to H Wang).
DISCLOSURE
The authors declare that they have no
competing interests as defined by Molecular Medicine, or other interests that
might be perceived to influence the results and discussion reported in this
paper.
REFERENCES
1. Mimura Y, Sakisaka S, Harada M, Sata M,
Tanikawa K. (1995) Role of hepatocytes in direct
clearance of lipopolysaccharide in rats. Gastroenterology. 109:1969–76.
2. Wang H, et al. (1999) HMG-1 as a late mediator of
endotoxin lethality in mice. Science. 285:248–251.
3. Yang H, et al. (2015) MD-2 is required for disulfide HMGB1-dependent TLR4 signaling. J. Exp.
Med. 212:5–14.
4. Andersson U, Tracey KJ. (2011) HMGB1 is a therapeutic target for sterile inflammation and infection. Annu. Rev. Immunol. 29:139–62.
5. Andersson U, et al. (2000) High mobility group 1
protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J. Exp.
Med. 192:565–70.
6. Qin S, et al. (2006) Role of HMGB1 in apoptosismediated sepsis lethality. J. Exp. Med. 203:1637–42.
7. Ye C, et al. (2012) Human macrophage and dendritic cell-specific silencing of high-mobility
group protein B1 ameliorates sepsis in a humanized mouse model. Proc. Natl. Acad. Sci. U. S. A.
109:21052–7.
8. Chavan SS, et al. (2012) HMGB1 mediates cognitive impairment in sepsis survivors. Mol. Med.
18:930–7.
9. Tian J, et al. (2007) Toll-like receptor 9-dependent
activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat.
Immunol. 8:487–96.
10. Yanai H, et al. (2009) HMGB proteins function as
universal sentinels for nucleic-acid-mediated innate immune responses. Nature. 462:99–103.
11. Xu J, et al. (2014) Macrophage endocytosis of
high-mobility group box 1 triggers pyroptosis.
Cell Death Differ. 21:1229–39.
12. Matzinger P. (1994) Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12:991–1045.
13. Scaffidi P, Misteli T, Bianchi ME. (2002) Release
of chromatin protein HMGB1 by necrotic cells
triggers inflammation. Nature. 418:191–5.
14. Ombrellino M, et al. (1999) Increased serum con-

M O L M E D 2 1 ( S U P P L E M E N T 1 ) , S 6 - S 1 2 , 2 0 1 5 | YA N G E T A L . | S 1 1

HMGB1 AS A DAMP

15.

16.

17.

18.

19.

20.

21.

22.

23.

24.

25.

26.

27.

28.

29.

30.

31.

centrations of high-mobility-group protein 1 in
haemorrhagic shock. Lancet. 354:1446–7.
Sodhi CP, et al. (2015) Intestinal epithelial TLR-4
activation is required for the development of
acute lung injury after trauma/hemorrhagic
shock via the release of HMGB1 from the gut.
J. Immunol. 194:4931–9.
Goldstein RS, et al. (2006) Elevated high-mobility
group box 1 levels in patients with cerebral and
myocardial ischemia. Shock. 25:571–4.
Tsung A, et al. (2005) The nuclear factor HMGB1
mediates hepatic injury after murine liver ischemia-reperfusion. J. Exp. Med. 201:1135–43.
Kokkola R, et al. (2003) Successful treatment of
collagen-induced arthritis in mice and rats by
targeting extracellular high mobility group box
chromosomal protein 1 activity. Arthritis Rheum.
48:2052–8.
Ostberg T, et al. (2010) Protective targeting of
high mobility group box chromosomal protein 1
in a spontaneous arthritis model. Arthritis Rheum.
62:2963–72.
Stros M. (2010) HMGB proteins: interactions with
DNA and chromatin. Biochim. Biophys. Acta.
1799:101–13.
Li J, et al. (2003) Structural basis for the proinflammatory cytokine activity of high mobility
group box 1. Mol. Med. 9:37–45.
Yang H, et al. (2004) Reversing established sepsis
with antagonists of endogenous high-mobility
group box 1. Proc. Natl. Acad. Sci. U. S. A.
101:296–301.
Yang H, et al. (2012) Redox modification of cysteine residues regulates the cytokine activity of
high mobility group box-1 (HMGB1). Mol. Med.
18:250–9.
Yang H, et al. (2010) A critical cysteine is required
for HMGB1 binding to toll-like receptor 4 and activation of macrophage cytokine release. Proc.
Natl. Acad. Sci. U. S. A. 107:11942–7.
Venereau E, et al. (2012) Mutually exclusive redox
forms of HMGB1 promote cell recruitment or
proinflammatory cytokine release. J. Exp. Med.
209:1519–28.
Lu B, et al. (2014) JAK/STAT1 signaling promotes
HMGB1 hyperacetylation and nuclear translocation. Proc. Natl. Acad. Sci. U. S. A. 111:3068–73.
Lamkanfi M, et al. (2010) Inflammasome-dependent release of the alarmin HMGB1 in endotoxemia. J. Immunol. 185:4385–92.
Lu B, et al. (2012) Novel role of PKR in inflammasome activation and HMGB1 release. Nature.
488:670–4.
Gardella S, et al. (2002) The nuclear protein
HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO
Rep. 3:995–1001.
Lu B, et al. (2014) Alpha7 nicotinic acetylcholine
receptor signaling inhibits inflammasome activation by preventing mitochondrial DNA release.
Mol. Med. 20:350–8.
Yanai H, et al. (2013) Conditional ablation of
HMGB1 in mice reveals its protective function

32.

33.

34.

35.

36.

37.

38.

39.

40.

41.

42.

43.

44.

45.

against endotoxemia and bacterial infection. Proc.
Natl. Acad. Sci. U. S. A. 110:20699–704.
Chen GY, Tang J, Zheng P, Liu Y. (2009) CD24
and Siglec-10 selectively repress tissue damageinduced immune responses. Science. 323:1722–5.
Degryse B, et al. (2001) The high mobility group
(HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization
in rat smooth muscle cells. J. Cell Biol.
152:1197–206.
Orlova VV, et al. (2007) A novel pathway of
HMGB1-mediated inflammatory cell recruitment
that requires Mac-1-integrin. EMBO J. 26:1129–39.
Chiba S, et al. (2012) Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat.
Immunol. 13:832–42.
Wahamaa H, et al. (2011) High mobility group
box protein 1 in complex with lipopolysaccharide or IL-1 promotes an increased inflammatory
phenotype in synovial fibroblasts. Arthritis Res.
Ther. 13:R136.
Sha Y, Zmijewski J, Xu Z, Abraham E. (2008)
HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J. Immunol.
180:2531–7.
Maugeri N, et al. (2014) Activated platelets present high mobility group box 1 to neutrophils, inducing autophagy and promoting the extrusion
of neutrophil extracellular traps. J. Thromb.
Haemost. 12:2074–88.
Balosso S, Liu J, Bianchi ME, Vezzani A. (2014)
Disulfide-containing high mobility group box-1
promotes N-methyl-D-aspartate receptor function and excitotoxicity by activating Toll-like receptor 4-dependent signaling in hippocampal
neurons. Antioxid. Redox. Signal 21:1726–40.
Yang H, Antoine DJ, Andersson U, Tracey KJ.
(2013) The many faces of HMGB1: molecular
structure-functional activity in inflammation,
apoptosis, and chemotaxis. J. Leukoc. Biol.
93:865–73.
Hreggvidsdottir HS, et al. (2009) The alarmin
HMGB1 acts in synergy with endogenous and
exogenous danger signals to promote inflammation. J. Leukoc. Biol. 86:655–62.
Urbonaviciute V, et al. (2008) Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J. Exp. Med. 205:3007–18.
Huttunen HJ, Fages C, Rauvala H. (1999) Receptor for advanced glycation end products (RAGE)mediated neurite outgrowth and activation of
NF-kappaB require the cytoplasmic domain of
the receptor but different downstream signaling
pathways. J. Biol. Chem. 274:19919–24.
Rouhiainen A, Kuja-Panula J, Tumova S, Rauvala
H. (2013) RAGE-mediated cell signaling. Methods
Mol. Biol. 963:239–63.
Kokkola R, et al. (2005) RAGE is the major receptor for the proinflammatory activity of HMGB1
in rodent macrophages. Scand. J. Immunol. 61:1–9.

S 1 2 | YA N G E T A L . | M O L M E D 2 1 ( S U P P L E M E N T 1 ) , S 6 - S 1 2 , 2 0 1 5

46. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle
AJ. (2010) HMGB1 and RAGE in inflammation
and cancer. Annu. Rev. Immunol. 28:367–88.
47. Qin YH, et al. (2009) HMGB1 enhances the proinflammatory activity of lipopolysaccharide by
promoting the phosphorylation of MAPK p38
through receptor for advanced glycation end
products. J. Immunol. 183:6244–50.
48. LeBlanc PM, et al. (2014) An immunogenic peptide in the A-box of HMGB1 protein reverses
apoptosis-induced tolerance through RAGE receptor. J. Biol. Chem. 289:7777–86.
49. Wang H, Yang H, Czura CJ, Sama AE, Tracey KJ.
(2001) HMGB1 as a late mediator of lethal systemic inflammation. Am. J. Respir. Crit. Care Med.
164(10 Pt 1):1768–73.

Cite this article as: Yang H, Wang H, Chavan SS,
Andersson U. (2015) High mobility group box protein 1 (HMGB1): the prototypical endogenous
danger molecule. Mol. Med. 21 Suppl 1:S6–12.

